Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match Biodexa Pharmaceuticals PLC (“Biodexa” ...
LONDON, ONTARIO -- (Marketwire) -- 05/18/11 -- Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that it has initiated a project to develop an optimal oral formulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results